Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona Mas Casanovas 90, Barcelona 08041, Spain.
Immunotherapy. 2021 Mar;13(4):327-344. doi: 10.2217/imt-2020-0253. Epub 2021 Jan 12.
Atopic dermatitis (AD) is a prevalent inflammatory skin disease. IL-13 contributes significantly to the pathogenesis of AD in several ways, and beneficial results have been demonstrated with anti-IL-13 therapies. Currently, the only monoclonal antibody (mAb) approved for AD treatment is dupilumab, an antagonist of the IL-4 receptor alpha (IL-4Rα) subunit common to IL-4 and IL-13 receptors, but clinical trials evaluating anti-IL-13 mAbs are providing promising results. The topics of this review will be mAbs targeting IL-13 for the treatment of AD such as dupilumab, tralokinumab and lebrikizumab, small molecules targeting the IL-13 pathway, and a brief explanation of therapies targeting IL-13 for the treatment of other skin diseases.
特应性皮炎（AD）是一种常见的炎症性皮肤病。IL-13 通过多种方式显著促进 AD 的发病机制，抗 IL-13 治疗已显示出有益的结果。目前，唯一批准用于 AD 治疗的单克隆抗体（mAb）是 dupilumab，它是 IL-4 和 IL-13 受体共有的 IL-4 受体 alpha（IL-4Rα）亚单位的拮抗剂，但评估抗 IL-13 mAb 的临床试验正在提供有希望的结果。本综述的主题将是针对 AD 的治疗靶点为 IL-13 的 mAb，如 dupilumab、tralokinumab 和 lebrikizumab、靶向 IL-13 通路的小分子，以及简要解释靶向 IL-13 治疗其他皮肤疾病的疗法。
